Fred Alger Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Fred Alger Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-30,000	Closed	-$746K	–	582
2018 Q3	$746K	Hold	30,000	–	–	﹤0.01%	340
2018 Q2	$824K	Sell	30,000 -13,915	-32%	-$418K	﹤0.01%	341
2018 Q1	$1.35M	Buy	43,915 +18,915	+76%	+$609K	0.01%	315
2017 Q4	$894K	Buy	+25,000	New	+$718K	﹤0.01%	342
2016 Q2	–	Sell	-84,288	Closed	-$1.47M	–	572
2016 Q1	$1.47M	Sell	84,288 -110,528	-57%	-$2.25M	0.01%	342
2015 Q4	$6.66M	Buy	+194,816	New	+$6.75M	0.03%	221

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Fred Alger Management's RVNC Position: Q4 2018 in Review

Fred Alger Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2018, closing a stake of 30,000 shares — an estimated $746K sold.

Fred Alger Management first reported a position in RVNC in Q4 2015 and held it in 6 quarters. The position peaked at $6.66M in Q4 2015. 101 funds tracked by Wall St. Rank hold RVNC as of Q4 2018.

Fred Alger Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Fred Alger Management sold 30,000 Revance Therapeutics, Inc. shares in Q4 2018, an estimated $746K.
Fred Alger Management first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 6 quarters.
Fred Alger Management's Revance Therapeutics, Inc. position peaked at $6.66M in Q4 2015.
101 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2018.

Based on Fred Alger Management's 13F filing for Q4 2018, filed 14 Feb 2019.